Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 12, Issue 9, Pages 2048-2074Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-022-01147-0
Keywords
Hepatotoxicity; 3D models; Nanobiomaterials; Liver; Nanomedicine
Funding
- IReL Consortium
- European Union H2020 framework programme under the REFINE project [761104]
Ask authors/readers for more resources
Despite the wide applications of nanobiomaterials (NBMs) in human health, their translation from lab to clinic is slow due to liver accumulation and toxicity. The commonly used in vitro and in vivo methods are insufficient in predicting NBM hepatotoxicity, posing a significant challenge. This review discusses the relationship between NBMs and the liver, limitations of toxicity assessment methods, recent advancements in tissue-mimetic 3D cell models, and the low public acceptance and limited uptake of these models.
Despite the exciting properties and wide-reaching applications of nanobiomaterials (NBMs) in human health and medicine, their translation from bench to bedside is slow, with a predominant issue being liver accumulation and toxicity following systemic administration. In vitro 2D cell-based assays and in vivo testing are the most popular and widely used methods for assessing liver toxicity at pre-clinical stages; however, these fall short in predicting toxicity for NBMs. Focusing on in vitro and in vivo assessment, the accurate prediction of human-specific hepatotoxicity is still a significant challenge to researchers. This review describes the relationship between NBMs and the liver, and the methods for assessing toxicity, focusing on the limitations they bring in the assessment of NBM hepatotoxicity as one of the reasons defining the poor translation for NBMs. We will then present some of the most recent advances towards the development of more biologically relevant in vitro liver methods based on tissue-mimetic 3D cell models and how these could facilitate the translation of NBMs going forward. Finally, we also discuss the low public acceptance and limited uptake of tissue-mimetic 3D models in pre-clinical assessment, despite the demonstrated technical and ethical advantages associated with them.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available